The Maximum Tolerated Dose (MTD) of Oral Clofarabine in Adult Patients With Relapsed CD20+ Non-Hodgkin Lymphoma(NHL) [clinicaltrials_resource:NCT00691652/outcome/1]
outcome [clinicaltrials_vocabulary:outcome]
The Maximum Tolerated Dose (MTD) of Oral Clofarabine in Adult Patients With Relapsed CD20+ Non-Hodgkin Lymphoma(NHL) [clinicaltrials_resource:NCT00691652/outcome/1]
Bio2RDF identifier
NCT00691652/outcome/1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00691652/outcome/1
group [clinicaltrials_vocabulary:group]
measure [clinicaltrials_vocabulary:measure]
safety issue [clinicaltrials_vocabulary:safety-issue]
time frame [clinicaltrials_vocabulary:time-frame]
14 days for up to 8 cycles (1 ...... for a total of up to 224 days
Duration of the study, up to 1 year.
One year after study drug(s) have been given. Duration of study up to 1 year.
Oral Clofarabine x 14 days for ...... to 8 cycles on day 1 of cycle
Twice monthly at standard of care visits for 3 months post last cycle of chemotherapy.
type [clinicaltrials_vocabulary:type]
alternate
The Maximum Tolerated Dose (MT ...... D20+ Non-Hodgkin Lymphoma(NHL)
@en
identifier
clinicaltrials_resource:NCT00691652/outcome/1
title
Initially, 3 patients will be ...... um tolerated dose is exceeded.
@en
type
label
The Maximum Tolerated Dose (MT ...... esource:NCT00691652/outcome/1]
@en